A Pilot Case Series Investigating the Efficacy of Sequential Stereotactic Body Radiotherapy and Tislelizumab Following Platinum-Doublet Chemotherapy in Patients with Stage IIIB/C–IV Non-Squamous Non-Small Cell Lung Cancer

1

This pilot case series included patients with unresectable stage IIIB/C–IV non-squamous NSCLC lacking actionable driver mutations.
2

The study reported a 1-year progression-free survival rate of 25% and a median overall survival of 26.89 months.
3

Treatment-related adverse events occurred in all patients, with 62.5% experiencing grade ≥3 adverse events.
4

The best overall response rate was 87.5%, with 7 patients achieving partial response and 1 achieving stable disease.
5

The findings are preliminary and cannot support definitive conclusions or clinical recommendations without further research.

1